Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MGNX's Cash-to-Debt is ranked higher than
75% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.84
MGNX's Equity-to-Asset is ranked higher than
74% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MGNX: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
MGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.26  Med: 0.83 Max: 0.9
Current: 0.84
-0.26
0.9
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
68% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 6.21
Beneish M-Score: -7.83
WACC vs ROIC
26.20%
-3062.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1232.33
MGNX's Operating Margin % is ranked higher than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. MGNX: -1232.33 )
Ranked among companies with meaningful Operating Margin % only.
MGNX' s Operating Margin % Range Over the Past 10 Years
Min: -1232.33  Med: -9.69 Max: 12.86
Current: -1232.33
-1232.33
12.86
Net Margin % -1216.17
MGNX's Net Margin % is ranked higher than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. MGNX: -1216.17 )
Ranked among companies with meaningful Net Margin % only.
MGNX' s Net Margin % Range Over the Past 10 Years
Min: -1216.17  Med: -10.21 Max: 13.1
Current: -1216.17
-1216.17
13.1
ROE % -53.83
MGNX's ROE % is ranked higher than
59% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. MGNX: -53.83 )
Ranked among companies with meaningful ROE % only.
MGNX' s ROE % Range Over the Past 10 Years
Min: -53.83  Med: -14.69 Max: -0.74
Current: -53.83
-53.83
-0.74
ROA % -46.81
MGNX's ROA % is ranked higher than
58% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. MGNX: -46.81 )
Ranked among companies with meaningful ROA % only.
MGNX' s ROA % Range Over the Past 10 Years
Min: -46.81  Med: -3.93 Max: 14.36
Current: -46.81
-46.81
14.36
ROC (Joel Greenblatt) % -469.47
MGNX's ROC (Joel Greenblatt) % is ranked higher than
55% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. MGNX: -469.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -648.31  Med: -88.92 Max: 250.31
Current: -469.47
-648.31
250.31
3-Year Revenue Growth Rate -32.10
MGNX's 3-Year Revenue Growth Rate is ranked lower than
79% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MGNX: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.5  Med: -62.2 Max: -32.1
Current: -32.1
-68.5
-32.1
3-Year EPS without NRI Growth Rate 248.30
MGNX's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. MGNX: 248.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 248.3
Current: 248.3
0
248.3
GuruFocus has detected 2 Warning Signs with Macrogenics Inc $MGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MGNX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MGNX Guru Trades in Q3 2016

Paul Tudor Jones 15,542 sh (+20.87%)
First Eagle Investment 221,800 sh (unchged)
John Griffin 1,360,000 sh (unchged)
Julian Robertson 266,067 sh (-15.03%)
Ronald Muhlenkamp 12,162 sh (-23.20%)
Steven Cohen 1,813,300 sh (-29.03%)
» More
Q4 2016

MGNX Guru Trades in Q4 2016

Ronald Muhlenkamp 12,803 sh (+5.27%)
John Griffin 1,360,000 sh (unchged)
Paul Tudor Jones 14,959 sh (-3.75%)
Julian Robertson 239,667 sh (-9.92%)
First Eagle Investment 175,000 sh (-21.10%)
Steven Cohen 1,213,117 sh (-33.10%)
» More
Q1 2017

MGNX Guru Trades in Q1 2017

Jim Simons 130,923 sh (New)
Ronald Muhlenkamp 13,167 sh (+2.84%)
Julian Robertson 239,667 sh (unchged)
John Griffin 1,360,000 sh (unchged)
First Eagle Investment Sold Out
Steven Cohen 1,180,817 sh (-2.66%)
Paul Tudor Jones 13,759 sh (-8.02%)
» More
Q2 2017

MGNX Guru Trades in Q2 2017

Jim Simons 227,023 sh (+73.40%)
Julian Robertson 239,667 sh (unchged)
Ronald Muhlenkamp 13,167 sh (unchged)
John Griffin Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 1,084,417 sh (-8.16%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2017-03-31 Add 2.84%$17.61 - $21.39 $ 17.22-11%13,167
First Eagle Investment 2017-03-31 Sold Out 0.01%$17.61 - $21.39 $ 17.22-11%0
Julian Robertson 2016-12-31 Reduce -9.92%0.19%$18.36 - $30.95 $ 17.22-32%239,667
First Eagle Investment 2016-12-31 Reduce -21.10%$18.36 - $30.95 $ 17.22-32%175,000
Ronald Muhlenkamp 2016-12-31 Add 5.27%$18.36 - $30.95 $ 17.22-32%12,803
Julian Robertson 2016-09-30 Reduce -15.03%0.41%$25.87 - $32.37 $ 17.22-42%266,067
Ronald Muhlenkamp 2016-09-30 Reduce -23.20%0.04%$25.87 - $32.37 $ 17.22-42%12,162
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CTMX, NAS:ANAB, NAS:VSAR, NAS:RXDX, NAS:CHRS, NAS:INSY, NAS:KALA, NAS:DOVA, NAS:PRTK, NAS:MCRB, NAS:ACRS, NAS:ALDR, NAS:BOLD, NAS:ABEO, NAS:AMAG, NAS:AKAO, NAS:LJPC, NAS:ANIP, NAS:TYME, NAS:GTHX » details
Traded in other countries:M55.Germany,
Headquarter Location:USA
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Ratios

vs
industry
vs
history
PB Ratio 2.70
MGNX's PB Ratio is ranked higher than
66% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. MGNX: 2.70 )
Ranked among companies with meaningful PB Ratio only.
MGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 3.42 Max: 12.83
Current: 2.7
1.73
12.83
PS Ratio 49.71
MGNX's PS Ratio is ranked higher than
63% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. MGNX: 49.71 )
Ranked among companies with meaningful PS Ratio only.
MGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.21  Med: 9.27 Max: 55.97
Current: 49.71
1.21
55.97
EV-to-EBIT -2.62
MGNX's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. MGNX: -2.62 )
Ranked among companies with meaningful EV-to-EBIT only.
MGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -77  Med: -7.05 Max: 2441.2
Current: -2.62
-77
2441.2
EV-to-EBITDA -2.80
MGNX's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. MGNX: -2.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
MGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -96.8  Med: -8.05 Max: 573.9
Current: -2.8
-96.8
573.9
EV-to-Revenue 32.36
MGNX's EV-to-Revenue is ranked higher than
76% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. MGNX: 32.36 )
Ranked among companies with meaningful EV-to-Revenue only.
MGNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 7.3 Max: 37.4
Current: 32.36
2
37.4
Current Ratio 8.37
MGNX's Current Ratio is ranked higher than
78% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. MGNX: 8.37 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 8.37 Max: 17.84
Current: 8.37
1.32
17.84
Quick Ratio 8.37
MGNX's Quick Ratio is ranked higher than
79% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. MGNX: 8.37 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.32  Med: 8.37 Max: 17.84
Current: 8.37
1.32
17.84
Days Sales Outstanding 60.15
MGNX's Days Sales Outstanding is ranked higher than
91% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. MGNX: 60.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.43  Med: 12.15 Max: 60.15
Current: 60.15
4.43
60.15

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.50
MGNX's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. MGNX: -11.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -216.5  Med: -201.1 Max: -11.5
Current: -11.5
-216.5
-11.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.16
MGNX's Price-to-Net-Cash is ranked higher than
79% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. MGNX: 3.16 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.29  Med: 4.13 Max: 9.94
Current: 3.16
2.29
9.94
Price-to-Net-Current-Asset-Value 3.06
MGNX's Price-to-Net-Current-Asset-Value is ranked higher than
80% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. MGNX: 3.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.25  Med: 3.77 Max: 9.52
Current: 3.06
2.25
9.52
Price-to-Tangible-Book 2.73
MGNX's Price-to-Tangible-Book is ranked higher than
73% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. MGNX: 2.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.16  Med: 3.47 Max: 8.75
Current: 2.73
2.16
8.75
Price-to-Median-PS-Value 5.37
MGNX's Price-to-Median-PS-Value is ranked higher than
66% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MGNX: 5.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.99 Max: 5.56
Current: 5.37
0.14
5.56
Earnings Yield (Greenblatt) % -38.04
MGNX's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. MGNX: -38.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47.8  Med: -4.85 Max: 1.5
Current: -38.04
-47.8
1.5

More Statistics

Revenue (TTM) (Mil) $12.08
EPS (TTM) $ -4.19
Beta4.00
Short Percentage of Float11.00%
52-Week Range $14.36 - 32.68
Shares Outstanding (Mil)36.80

Analyst Estimate

Dec17 Dec19 Dec20
Revenue (Mil $) 38 15 110
EPS ($) -3.64 -4.44 -3.33
EPS without NRI ($) -3.64 -4.44 -3.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
7 Negative Assets in Gurus' Portfolios Sep 15 2017 
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO Co Sep 10 2017 
MacroGenics Advances Two First-in-Class Clinical DART® Molecules Sep 05 2017 
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen Aug 31 2017 
MacroGenics to Participate in Three Investor Conferences in September Aug 30 2017 
MacroGenics to Present at the Wedbush PacGrow Healthcare Conference Aug 09 2017 
Gurus' Worst-Performing Stocks Aug 04 2017 
MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call Jul 26 2017 
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Accepted for Oral Pr Jul 17 2017 
MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheuma Jun 17 2017 

More From Other Websites
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : September 13,... Sep 13 2017
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO... Sep 10 2017
MacroGenics Advances Two First-in-Class Clinical DART® Molecules Sep 05 2017
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen Aug 31 2017
MacroGenics to Participate in Three Investor Conferences in September Aug 30 2017
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : August 25, 2017 Aug 25 2017
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
Edited Transcript of MGNX earnings conference call or presentation 2-Aug-17 8:30pm GMT Aug 13 2017
MacroGenics to Present at the Wedbush PacGrow Healthcare Conference Aug 09 2017
MacroGenics reports 2Q loss Aug 02 2017
MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results Aug 02 2017
Investor Network: MacroGenics, Inc. to Host Earnings Call Aug 02 2017
MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call Jul 26 2017
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Accepted for Oral... Jul 17 2017
ETFs with exposure to MacroGenics, Inc. : June 8, 2017 Jun 08 2017
MacroGenics, Inc. breached its 50 day moving average in a Bullish Manner : MGNX-US : June 5, 2017 Jun 05 2017
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : May 9, 2017 May 09 2017
ETFs with exposure to MacroGenics, Inc. : May 8, 2017 May 08 2017
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}